A growing library of the omega-3 research we're following — summarized and categorized so you can find what matters to you.
Adjunctive omega-3 supplementation improved a skin flush biomarker in schizophrenia patients, especially those with the weakest baseline response.
In lab experiments, omega-3-derived compounds DHEA and EPEA reduced inflammatory activity in brain immune cells and lessened stress signals sent to neurons, acting through cannabinoid receptors.
In a mouse model of severe alcohol-related liver disease, resolvin D1 reduced liver injury, inflammation, and fibrosis-related gene activity while improving liver regeneration.
DHA supplementation reduced post-meal inflammation markers and improved blood vessel responsiveness after a high-fat breakfast, while blueberry powder only reduced inflammation markers.
In mothers of preterm infants, breast milk levels of AA and DHA declined over 3 weeks, but many of their bioactive breakdown products (oxylipins) remained stable or rose.
EPA appears to reduce oxidative stress in liver cells by regulating two separate microRNA pathways tied to mitochondrial health and antioxidant enzymes.
Nearly 40% of Italian patients prescribed EPA/DHA used it alone rather than combined with other cholesterol-lowering therapy, often outside current cardiovascular guideline recommendations.
Pooling nine trials, omega-3 supplements added to standard gum disease treatment showed modestly better outcomes than treatment alone, though evidence quality was rated low.
A single dose of DHA reduced binge-like drinking of alcohol, sugar water, and sweeteners in mice without affecting movement or anxiety levels.